The Hindu Editorial Analysis- 31st December 2024

UPI Duopoly's Rise and Market Vulnerabilities

Why in News?

The article discusses the risks of market concentration in India's UPI ecosystem and its implications for competition and innovation.

Rise of Unified Payments Interface (UPI) in India

• UPI's Dominance: Since its introduction, the Unified Payments Interface (UPI) has surged in popularity, now representing nearly 80% of all digital transactions in India.
• Record Transactions: In August 2024, the UPI ecosystem processed a staggering ₹20.60 lakh crore in transactions.
• Trust in Digital Payments: This rapid growth is noteworthy, especially in a country with a historical reliance on cash and limited digital literacy, highlighting UPI's role in fostering trust in digital payment methods.

Challenges to UPI's Continued Success

• Current Penetration: UPI currently reaches 30% of the population, indicating substantial progress but also revealing a vast untapped potential.
• Future Expansion: To integrate the remaining 70% of the population into the digital payment framework, advancements in app design, service offerings, and the overall product ecosystem will be essential.

Market Concentration and Risks

• Dominance of TPAPs: PhonePe and Google Pay together dominate over 85% of the UPI market.
• Paytm's Position: Paytm, the third-largest player, holds a mere 7.2% market share, contributing to a highly concentrated market.

Risks of Market Concentration

• Systemic Vulnerability: The dominance of PhonePe and Google Pay creates potential single points of failure within the system. A sudden disruption in their services could have widespread repercussions across India's financial ecosystem.
• Decreased Competition and Innovation: The large scale and user bases of these dominant TPAPs hinder competition from smaller players. The zero-charge model pushes service providers to prioritize scale over innovation, stifling creative advancements.
• Foreign Ownership Concerns: Both leading TPAPs are foreign-owned, with PhonePe under Walmart and Google Pay under Google. This raises issues regarding data security and foreign influence in a vital financial infrastructure. Encouraging the growth of Indian TPAPs could mitigate these risks.

Path to a Robust and Inclusive UPI Ecosystem

• Level Playing Field: It is essential to create a fair environment for Indian developers and smaller players to foster the next phase of UPI's growth.
• Market Share Caps: Implementing caps on market share and offering suitable incentives can promote competition, innovation, and resilience within the ecosystem.
• Safeguarding Public Trust: Ensuring fairness and addressing potential risks is crucial to maintaining public trust and allowing UPI to realize its transformative potential.

Conclusion

• UPI's future hinges on public trust, which must be upheld through continuous innovation, reliability, and resilience.
• However, the current market concentration, particularly by foreign-owned entities, poses significant challenges to competition and security.
• To ensure sustained growth, it is vital to establish a balanced ecosystem that provides equal opportunities for Indian players.
•  Regulatory interventions, such as market share caps, are essential to mitigate the risks of monopolistic dominance and foster a more inclusive and competitive environment.

States and the Danger of Poorly Manufactured Drugs

Why in News?

 Recent incidents involving drugs of Not of Standard Quality (NSQ) have raised serious concerns in India. In Ballari, Karnataka, five young mothers reportedly died due to contaminated drugs produced by a pharmaceutical company in West Bengal. This tragic event has brought to light the regulatory challenges and public health risks associated with the sale of poorly manufactured drugs across the country. 

Regulatory Challenges

•  The Drugs and Cosmetics Act of 1940 permits pharmaceutical companies to sell their drugs nationwide, even if they are licensed and inspected only in the state where the manufacturing facility is located. 
•  This regulatory loophole makes it challenging for states like Karnataka to prevent substandard drugs from entering local pharmacies, posing significant public health threats. 

Problems Faced by States

•  Some states encounter difficulties in addressing drugs produced outside their jurisdiction. 
•  Drug inspectors are limited to prosecuting pharmaceutical companies, which is a lengthy process. 
•  During the trial period, manufacturers from other states can continue selling their products, as only the drug inspectors from the manufacturing state have the authority to cancel or suspend manufacturing licenses. 

Proposed Solutions

• Cost-effective Solutions: One proposed solution is to enhance information sharing between drug control departments of different states and public procurement agencies. 
• Centralized Database: Establishing a centralized database of test results from central and state drug testing laboratories would enable drug inspectors and procurement officials to monitor drug failures across states. This approach would facilitate risk-based enforcement and procurement decisions. 
• Centralized Inspection Reports: Making centralized inspection reports and licensing information from state drug inspectors available in a single database would help procurement agencies verify the credentials of pharmaceutical companies, reducing the risk of purchasing low-quality drugs. 

Benefits of a Centralized Database

•  A centralized database would aid procurement agencies and state agencies in verifying the quality of pharmaceutical manufacturers before purchasing drugs. 
•  This system could prevent incidents like the recent scandal in Maharashtra, where spurious antibiotics were supplied to public hospitals. 
•  By tracking manufacturers with poor inspection records, procurement officers can prioritize suppliers from states known for stringent inspections, ultimately enhancing public health outcomes. 

Additional Recommendations

• Central Register: The Union Ministry of Health should establish a central register to document pharmaceutical manufacturers blacklisted by procurement agencies for supplying NSQ drugs. This measure would help eliminate unreliable players from the market. 
• Empowering States: States should be granted legal authority to prohibit manufacturers from other states from selling drugs within their jurisdiction if the drugs have caused adverse health effects, such as fatalities, until the manufacturers rectify the issues. 

Conclusion

 The issue of NSQ drugs in India underscores significant regulatory deficiencies and public health risks. Strengthening information sharing through centralized databases has the potential to enhance drug quality control. Additionally, empowering states with legal authority and advocating for legislative reforms will contribute to better monitoring and enforcement, ultimately improving drug safety across the nation.